Epitel Taps Medtech Veteran Reinstein to Scale Brain Health Tech

SALT LAKE CITY, UT – September 15, 2026 – In a strategic move that signals a major commercial offensive, digital health innovator Epitel has appointed seasoned medtech leader James Reinstein to its Board of Directors. The appointment comes just two months after the company secured a $26 million Series B financing round aimed squarely at accelerating the market penetration of its flagship REMI® Remote EEG Monitoring System. This combination of fresh capital and veteran leadership underscores a pivotal moment for Epitel as it transitions from a promising R&D firm to a formidable commercial force in the burgeoning digital neurology space.

Reinstein is not just another board appointment; he is a specialist in corporate scaling and successful exits. His appointment is a clear indicator of Epitel’s ambition to transform the standard of care for seizure detection and diagnosis. For a company at this critical growth juncture, bringing in a leader with a proven playbook for commercialization is a move that resonates with investors and industry watchers alike.

The Strategic Playmaker for a Growth-Stage Innovator

James Reinstein’s track record reads like a blueprint for medtech success. He most recently served as President and CEO of Conformal Medical, a company he guided from an emerging developer of a novel stroke prevention device to a successful acquisition by W. L. Gore & Associates in February 2026. This experience—taking an innovative technology, building its commercial strategy, and navigating a high-value exit—is precisely the expertise Epitel needs as it scales its own breakthrough technology.

Throughout his career, Reinstein has been instrumental in raising over $300 million in capital for emerging medical device companies and has led multiple successful transactions. His background also includes senior leadership roles at industry giants like LivaNova and Boston Scientific, providing him with a deep understanding of market dynamics across various geographies. Crucially, his experience extends directly into the epilepsy space, making his perspective immediately relevant to Epitel's initial market focus.

“He understands how to take innovative medical technologies and build the commercial strategy, teams and infrastructure needed to scale them,” said Josh Phillips, Chairman of Epitel’s Board of Directors. “As Epitel enters its next phase of growth, that combination of experience and judgment will be incredibly valuable to the company and the Board.”

This move is a classic example of a technology company preparing for its next act. With a validated, FDA-cleared product and significant new funding, the primary challenge shifts from innovation to execution. Reinstein’s role will be to provide the strategic oversight necessary to build a robust commercial engine, streamline distribution, and secure a dominant position in the market.

Redefining Neurological Diagnostics Beyond the Hospital Walls

The strategic importance of Reinstein’s appointment is magnified by the transformative potential of Epitel’s technology. The REMI® Remote EEG Monitoring System is designed to solve a fundamental problem in neurology: access. An estimated 9.2 million Americans experience seizures annually, yet a staggering 40% lack access to EEG testing, a cornerstone of diagnosis. This is often due to a lack of specialized equipment and personnel, with only about a quarter of U.S. hospitals having EEG capacity.

Epitel’s REMI system directly confronts this challenge. It is a fully wireless, wearable sensor system that allows for extended EEG monitoring for up to 30 days in a patient’s home. This is a dramatic improvement over traditional ambulatory EEGs, which are typically limited to 72 hours and frequently miss the infrequent, unpredictable seizure events that can delay a diagnosis for months or even years. The system’s usability is a key advantage; it can be applied quickly by non-specialized staff or even self-applied by patients, breaking down barriers to care.

Patient preference for the system has been overwhelmingly positive. In clinical studies, 100% of patients preferred REMI over traditional wired EEG systems, citing comfort, ease of use, and the freedom to remain mobile. This high level of patient adherence is critical for capturing the long-term data needed for an accurate diagnosis. The system's diagnostic yield is impressive, with one study showing it successfully met referral objectives in nearly 70% of cases.

Further bolstering its platform, Epitel has integrated artificial intelligence with its REMI Vigilenz™ AI technology, which automatically analyzes the vast datasets from long-duration recordings to flag potential seizure activity for clinician review. This AI-driven efficiency is crucial for making long-term monitoring practical for neurologists. The company has methodically secured five separate FDA 510(k) clearances for its hardware and software, most recently expanding its indication in March 2025 to include pediatric patients as young as one year old, a particularly vulnerable and underserved population.

A Bellwether for the Maturing Digital Neurology Market

Epitel’s aggressive growth strategy and high-profile board appointment are not happening in a vacuum. They are indicative of the broader maturation of the digital neurology market. The global Remote Neurological Monitoring market, valued at approximately $3.8 billion in 2026, is projected to swell to $5.8 billion by 2033. This growth is fueled by an aging population, the rising prevalence of neurological disorders, and a systemic shift toward decentralized, patient-centric healthcare.

Investors are taking notice, as evidenced by Epitel’s recent funding round co-led by Catalyst Health Ventures and Genoa Ventures. The company’s success in securing reimbursement using pre-existing billing codes is another critical piece of its strategic puzzle, de-risking adoption for healthcare providers and smoothing the path to commercial viability. While competitors like Ceribell, Zeto, and Empatica are also innovating, Epitel’s focus on ultra-long-term, at-home monitoring gives it a distinct advantage in capturing the full picture of a patient's neurological condition over time.

“I’m thrilled to be joining the Epitel Board of Directors at such an exciting point in the company’s journey,” Reinstein stated. “Epitel’s technology has the potential to meaningfully transform the way clinicians detect and manage neurological conditions.”

With a powerful combination of disruptive technology, substantial funding, a clear regulatory pathway, and now, a seasoned commercial strategist on its board, Epitel is strongly positioned to not only compete but lead. The company's next moves will be closely watched as a bellwether for the entire digital health industry, demonstrating how innovative technology, when paired with sharp business strategy, can create lasting value and fundamentally change patient care.